Abstract
Background
ST elevation myocardial infarction (STEMI) is classically characterized by total occlusion of the culprit coronary artery. However during primary percutaneous coronary intervention (PCI) thrombolysis in myocardial infarction (TIMI) 0 flow is not observed in all patients' culprit arteries in angiographic views. This study was conducted to find out the frequency of TIMI flow in acute STEMI patients in view of the above concept. The aim of this study was to evaluate the frequency of pre-procedural TIMI III flow in those patients who underwent primary PCI for acute STEMI in a public sector hospital in Karachi, Pakistan.
Methodology
This study is an audit of already saved data in the catheterization laboratory of the National Institute of Cardiovascular Diseases (NICVD), Karachi, that was collected prospectively from January 2016 to December 2018. These data were collected after taking consent from those patients who presented to hospital within 12 hours of symptoms and underwent primary PCI. Data were entered and analyzed on Statistical Package for the Social Sciences (SPSS) version 19 (IBM Corp., Armonk, NY, USA).
Results
A total of 8018 patients were included in this study who presented with STEMI and underwent primary PCI. Out of them 80.9% were males. Hypertension was the leading risk factor in 54.1% (4340) of patients. TIMI III flow was present in 11.4% of patients before primary PCI, while TIMI 0, I and II flow were present in 57.1%, 15.1%, and 16.3% of patients respectively (p<0.001). Fourteen percent of patients with TIMI III flow were of age group 51 to 60 years. Among those who had TIMI III flow, 11.2% were those with door to balloon time of <90 minutes. In 11% of cases, left anterior descending (LAD) artery had TIMI III flow as compared to other vessels (p<0.001). The length of the lesion was significantly smaller in patients who had TIMI III flow compared to those who had TIMI 0-II flow.
Conclusions
This study revealed that not all patients with acute STEMI had totally occluded culprit coronary artery but some of them had angiographic TIMI I-III flow in the infarct-related artery. Further studies are needed to find the reason for re-establishment of flow in the culprit vessel in STEMI patients before PCI.
Keywords: coronary artery disease, st elevation myocardial infarction, primary percutaneous coronary intervention, infarct related artery, spontaneous revascularization, thrombolysis in myocardial infarction, vessel patency
Introduction
Ischemic heart disease (IHD) is one of the major global causes of death. It is predicted that in 2020 cardiovascular disease is the leading cause of morbidity and mortality [1]. There are different treatment modalities for the treatment of IHD and percutaneous coronary intervention (PCI) is one of the best choices. In an acute setting, i.e. ST elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (pPCI) has a better outcome and is preferred over other treatment options [2]. In the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial, primary PCI was proven superior to thrombolytic therapy [3]. In primary PCI most important factor is blood flow in coronary arteries, which is measured by angiographic grading tool i.e. thrombolysis in myocardial infarction (TIMI) flow grade.
It is observed that patients with STEMI have different TIMI flow grades in coronary arteries; most of these patients have a completely occluded coronary artery but some patients have TIMI III flow in the coronary artery [4] which is sometimes due to spontaneous revascularization (SR) or due to medications (aspirin, GP IIb IIIa inhibiter, anticoagulation) given before pPCI. TIMI III flow is related to better outcomes of pPCI and less major adverse cardiovascular events (MACE) are observed in these patients [5]. It has been also studied that TIMI III flow or ST resolution (SR) has greater evidence of myocardial salvage with less chance of left ventricular failure and survival benefits i.e. 39% reduction in mortality [6,7].
In the ST-segment elevation acute myocardial infarction (ASSENT-4) trial, it was analyzed that those patients who have pre-PCI TIMI III flow have also higher TIMI flow after PCI, improved SR and better clinical outcome after 90 days of pPCI [8]. Thus TIMI III flow can bring extra benefits for the patients with STEMI and less chance of slow flow in coronary arteries after pPCI.
Frequency of TIMI III flow in pre-pPCI ranges between 10-30% [9,10]. This study was conducted to find out the frequency of TIMI III flow in acute STEMI. Recognition of those predictors which bring spontaneous revascularization in the culprit artery will provide new treatment information for STEMI and bring prognostic information.
Materials and methods
This study was a retrospective observational study that was done after approval from the ethical review committee (ERC #36/2020). It was done by reviewing hospital registry data that was collected from January 1, 2016 December 31, 2018 by the interventional cardiology department of the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. These data were collected by the cardiologist after taking consent from those patients who presented to hospital within 12 hours with symptoms of STEMI and underwent pPCI and questionnaire proforma was filled. All data were extracted from these pre-filled questionnaire proforma that include patient’s demographics and other variables like age, gender, risk factors, symptoms onset to hospital arrival and door to balloon time, number of vessels involved, culprit vessel, and lesion length, etc. Frequency of TIMI flow was calculated as TIMI 0, I, II and III, which are classified as follows: TIMI 0 flow, no perfusion to the myocardium after the occlusion of coronary artery (penetration without perfusion); TIMI 1 flow, incomplete filling of the distal coronary bed due to faint antegrade flow (partial perfusion); TIMI 2 flow, delayed and sluggish blood flow but with complete filling of the distal coronary bed (partial reperfusion); and TIMI 3 flow, normal blood flow in the coronary artery that fills the distal bed completely.
Two main groups were formed according to TIMI flow; one with TIMI 0-II flow and the other with TIMI III flow. Extracted data were entered into Statistical Package for the Social Sciences (SPSS) version 19 (IBM Corp., Armonk, NY, USA) and appropriate mean ± standard deviation (SD) or frequency percentages as descriptive statistics were computed for the quantitative and qualitative variables respectively. Bivariate analysis with Chi-square test and t-test/Mann-Whitney U test were performed to assess the associated factors with patency of coronary arteries. P-value ≤ 0.05 was considered statistical significant.
Results
In this study, 8018 patients were included who presented with STEMI and underwent pPCI within 12 hours of onset of symptoms. In Table 1, baseline demographic, clinical, and angiographic characteristics have been reported. Most of the patients in this study were male (80.9%). The majority of patients with STEMI were in the age group of 51-60 years. Hypertension was the leading risk factor in 54.1% of patients followed by diabetes mellitus (DM) in 30.7% and smoking in 27.9% of the patients. The majority (67.2%) of patients were those who presented to the hospital after 120 minutes of onset of symptoms.
Table 1. Baseline demographic, clinical, and angiographic characteristics.
SD = standard deviation, TIMI = thrombolysis in myocardial infarction
| Characteristics | Base |
| Total | 8018 |
| Gender | |
| Male | 80.9% (6489) |
| Female | 19.1% (1529) |
| Age | |
| Mean ± SD years | 54.85 ± 11.42 |
| Up to 40 years | 11.6% (929) |
| 41 to 50 years | 28.4% (2275) |
| 51 to 60 years | 34% (2726) |
| More than 60 years | 26% (2088) |
| Symptom onset to hospital arrival time | |
| Mean ± SD minutes | 218.01 ± 133.91 |
| ≤ 120 minutes | 32.8% (2630) |
| > 120 minutes | 67.2% (5388) |
| First Medical Contact (FMC) to Device time | |
| Mean ± SD minutes | 75.91 ± 55.26 |
| ≤ 90 minutes | 75.9% (6089) |
| > 90 minutes | 24.1% (1929) |
| Total ischemia Time | 293.92 ± 143.99 |
| Pre Procedural TIMI Flow Rate | |
| 0 | 57.1% (4579) |
| I | 15.1% (1212) |
| II | 16.3% (1309) |
| III | 11.4% (918) |
| Number of Vessels Involved | |
| Single vessel (SVD) | 38.3% (3067) |
| Two vessels (2VD) | 31.8% (2551) |
| Three vessels (3VD) | 29.6% (2374) |
| None | 0.3% (26) |
| Infarct Related Artery | |
| Left anterior descending (LAD) | 54.7% (4383) |
| Right coronary artery (RCA) | 32.9% (2635) |
| Left circumflex (LCX) | 11.1% (886) |
| Ramus | 0.2% (17) |
| Left main (LM) | 0.2% (16) |
| Diagonal | 0.6% (52) |
| None | 0.3% (22) |
| Other | 0.1% (7) |
Pre-procedural TIMI flow in 57.1% of patients was TIMI 0 while in 11.4% of patients it was TIMI III flow. Thirty-eight percent (38%) of our patients had single-vessel coronary artery disease while 29.6% had triple-vessel disease. Left anterior descending (LAD) was the culprit artery in 54.7% of cases as compared to other coronary arteries.
In Table 2 TIMI flow rate was calculated by demographic, clinical, and angiographic characteristics. Patients were divided into two groups on the basis of TIMI flow (TIMI 0-II and TIMI III). Younger patients up to 40 years of age had high TIMI III flow rate as compared the older age group (14.1% vs. 11.8% respectively; p=0.024). Symptoms onset to hospital arrival time remarkably affected the TIMI flow. Those patients who came to the hospital within 120 minutes of symptoms onset had a higher rate of TIMI III flow as compared to those who came after 120 minutes (12.6% and 10.9% respectively; p=0.026). Patients who had <90 minutes of first medical contact (FMC) to device time had a higher rate of TIMI 0-II as compared to those who had FMC to device time >90 minutes (11.2% and 12.4%, respectively). Among major coronary arteries, left circumflex (LCX) had a higher rate of TIMI III (12.2%) flow as compare to LAD and right coronary artery (RCA). However among all epicardial vessels, diagonal artery had maximum pre-procedure patency rate (21.2%; p<0.001) as compared to all other coronary arteries.
Table 2. Pre-procedure TIMI III flow rate by demographic, clinical, and angiographic characteristics.
SD = standard deviation, TIMI = thrombolysis in myocardial infarction
| Characteristics | Base (N) | TIMI III Flow Rate (%) | ||
| TIMI 0-2 | TIMI 3 | P-value | ||
| Total | 8018 | 88.6% (7100) | 11.4% (918) | - |
| Gender | ||||
| Male | 6489 | 88.6% (5750) | 11.4% (739) | 0.725 |
| Female | 1529 | 88.3% (1350) | 11.7% (179) | |
| Age | ||||
| Mean ± SD years | 54.8 ± 11.4 | 54.9 ± 11.3 | 54.2 ± 12.3 | 0.06 |
| Up to 40 years | 929 | 85.9% (798) | 14.1% (131) | 0.024* |
| 41 to 50 years | 2275 | 88.2% (2007) | 11.8% (268) | |
| 51 to 60 years | 2726 | 89.5% (2441) | 10.5% (285) | |
| More than 60 years | 2088 | 88.8% (1854) | 11.2% (234) | |
| Risk Factors | ||||
| Diabetes Mellitus | 2464 | 88.2% (2174) | 11.8% (290) | 0.549 |
| Hypertension | 4340 | 88.9% (3858) | 11.1% (482) | 0.294 |
| Smokers | 2237 | 88% (1969) | 12% (268) | 0.353 |
| Symptom Onset to Hospital Arrival time | ||||
| Mean ± SD minutes | 218 ± 133.9 | 219.2 ± 134.3 | 208.6 ± 130.4 | 0.015* |
| ≤ 120 minutes | 2630 | 87.4% (2299) | 12.6% (331) | 0.026* |
| > 120 minutes | 5388 | 89.1% (4801) | 10.9% (587) | |
| First Medical Contact (FMC) to Device time | ||||
| Mean ± SD minutes | 75.9 ± 55.3 | 75.4 ± 54.1 | 80 ± 63.1 | 0.211 |
| ≤ 90 minutes | 6089 | 88.8% (5410) | 11.2% (679) | 0.137 |
| > 90 minutes | 1929 | 87.6% (1690) | 12.4% (239) | |
| Total Ischemia Time | 293.9 ± 144 | 294.6 ± 144.3 | 288.6 ± 141.4 | 0.242 |
| Number of Vessels Involved | ||||
| Single vessel (SVD) | 3067 | 88.2% (2706) | 11.8% (361) | |
| Two vessels (2VD) | 2551 | 89.6% (2286) | 10.4% (265) | |
| Three vessels (3VD) | 2374 | 88.5% (2101) | 11.5% (273) | |
| None | 26 | 26.9% (7) | 73.1% (19) | |
| Infarct Related Artery | ||||
| Left anterior descending (LAD) | 4383 | 89% (3902) | 11% (481) | <0.001* |
| Right coronary artery (RCA) | 2635 | 88.6% (2335) | 11.4% (300) | |
| Left circumflex (LCX) | 886 | 87.8% (778) | 12.2% (108) | |
| Ramus | 17 | 94.1% (16) | 5.9% (1) | |
| Left main (LM) | 16 | 87.5% (14) | 12.5% (2) | |
| Diagonal | 52 | 78.8% (41) | 21.2% (11) | |
Discussion
The remarkable result of this study showed that not all culprit vessels in STEMI are completely occluded. It was calculated by measurement of TIMI flow rate in the culprit vessel. It was found that 11.4% of STEMI patients have TIMI III flow before pPCI, which is less than the previous studies (14-22%) [11-13]. It is well documented in the literature that myocardial infarction occurs due to plaque rupture that leads to thrombus formation in the coronary artery and that is the ultimate pathophysiology of the STEMI. Thrombus formation occurs due to imbalance between the coagulation pathway and fibrinolytic system [14] and ultimately endogenous fibrinolytic system dominate and spontaneous revascularization of the culprit vessel takes place [15,16]. There are multiple endogenous factors responsible for spontaneous revascularization. These factors potentiate the process of auto thrombolysis and include hepsin, cathepsin and tissue plasminogen activators u-PA, t-PA, release from white blood cells and endothelial cells [17].
Another important finding of this study was that those patients who had less FMC to device time have less TIMI III flow rate as compared to those who have >90 minutes. The possible explanations for this are the endogenous and exogenous mediators. The exogenous mediators are medications given before pPCI [18]. These medications are antithrombotic, e.g. aspirin, clopidogrel, ticagrelor, and prasugrel, and anticoagulation e.g. heparin and enoxaparin [19]. The values of clopidogrel and tirofiban to maintain TIMI III flow before pPCI were studied in STEMI patients and it was found that they increase the chance of spontaneous revascularization in such patients [20]. Aspirin and clopidogrel require almost two to four hours to achieve maximum effects,however, the time between the loading dosage of these medicines and pPCI was less than one hour so these drugs could not achieve peak therapeutic effects. There are some other medications that have rapid onset of action e.g. ticagrelor and prasugrel [21,22].
The relation between TIMI III flow was also related to some other factors, e.g. age and gender; young women have less coronary artery disease and they have more often TIMI III flow before PCI compared to similarly aged men [23]. In this study gender had no significant difference in TIMI flow but the younger age group had more pre-procedure TIMI flow rate as compared to the older age group.
It was also observed in this study that smoking has no significant effect on the angiographic TIMI flow rate in the culprit artery, however some studies revealed that pre-procedure TIMI flow rate was better in current smokers [24]. This study also showed that diabetes mellitus has no effect on pre-procedural TIMI flow rate. In other studies, diabetes mellitus has directly affected pre-pPCI TIMI flow rate but post-procedure there is no difference in TIMI flow rate in diabetic and non-diabetic patients [25]. It was found in this study that symptom onset to hospital arrival time has an effect on the pre-pPCI TIMI flow rate; those patients who came to the hospital earlier have a higher rate of TIMI III flow rate as compared to later comers. The relationship between the late arrival to hospital and TIMI III flow was proven by other studies; it was found that if total ischemic time is higher then there is less chance of TIMI III flow rate in STEMI patients [26,27].
It was found that the LAD is the most commonly involved artery in STEMI and this result was comparable to other studies [28,29]. Among all major coronary arteries, LCX had more TIMI III flow rate and the same result was found in another study [29]. This study also showed that TIMI III flow was more in small-length culprit lesions, however there is not enough data that support this finding.
This is a retrospective, non-randomized design study; we only audited the frequency of pre-procedure TIMI III flow in patients coming to our hospital for pPCI. We could not assess the causes of pre-procedural TIMI III flow; pre- and post-procedure left ventricular function and its impact on patient outcome can be evaluated by further prospective studies.
Conclusions
In this study we concluded that not all patients with STEMI have completely occluded culprit artery, which is proven by other studies. Further studies are required to find the relevant factors which are responsible for high TIMI III flow rate and to manage these factors so that spontaneous revascularization in STEMI can be achieved and ultimately can provide better outcome to the patients.
Acknowledgments
The authors wish to acknowledge the support of the doctors and staff members of the Clinical Research Department of the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained by all participants in this study. National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan issued approval ERC-36/2020. This study was approve by the ethical review committee of the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. J Am Coll Cardiol. 2012;60:1207–1216. doi: 10.1016/j.jacc.2012.03.074. [DOI] [PubMed] [Google Scholar]
- 2.Timely PCI for STEMI--still the treatment of choice. Bhatt DL. N Engl J Med. 2013;368:1446–1447. doi: 10.1056/NEJMe1302670. [DOI] [PubMed] [Google Scholar]
- 3.System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial) Nielsen PH, Terkelsen CJ, Nielsen TT, et al. Am J Cardiol. 2011;108:776–781. doi: 10.1016/j.amjcard.2011.05.007. [DOI] [PubMed] [Google Scholar]
- 4.Influence of angiographic spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment elevation myocardial infarction. Li X, Li B, Gao J, et al. Oncotarget. 2017;8:79767–79774. doi: 10.18632/oncotarget.19338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. Schaaf MJ, Mewton N, Rioufol G, et al. J Cardiol. 2016;67:248–253. doi: 10.1016/j.jjcc.2015.05.008. [DOI] [PubMed] [Google Scholar]
- 6.Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. Stone GW, Selker HP, Thiele H, et al. J Am Coll Cardiol. 2016;67:1674–1683. doi: 10.1016/j.jacc.2016.01.069. [DOI] [PubMed] [Google Scholar]
- 7.Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials) Brener SJ, Mehran R, Brodie BR, et al. Am J Cardiol. 2011;108:918–923. doi: 10.1016/j.amjcard.2011.05.022. [DOI] [PubMed] [Google Scholar]
- 8.Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study. Zeymer U, Huber K, Fu Y, et al. Eur Heart J Acute Cardiovasc Care. 2012;1:136–142. doi: 10.1177/2048872612447069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Fefer P, Hod H, Hammerman H, Boyko V, Behar S, Matetzky S. Am J Cardiol. 2009;103:149–153. doi: 10.1016/j.amjcard.2008.08.050. [DOI] [PubMed] [Google Scholar]
- 10.Relation of spontaneous reperfusion in ST-elevation myocardial infarction to more distal coronary culprit narrowings. Leibowitz D, Gerganski P, Nowatzky J, Weiss AT, Rott D. Am Heart J. 2008;101:308–310. doi: 10.1016/j.amjcard.2007.08.036. [DOI] [PubMed] [Google Scholar]
- 11.Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Stone GW, Cox D, Garcia E, et al. Circulation. 2001;104:636–641. doi: 10.1161/hc3101.093701. [DOI] [PubMed] [Google Scholar]
- 12.Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Fefer P, Hod H, Hammerman H, Boyko V, Behar S, Matetzky S, Acute Coronary Syndrome Israeli Survey (ACSIS) 2006 Study Group. Am J Cardiol. 2009;103:149–153. doi: 10.1016/j.amjcard.2008.08.050. [DOI] [PubMed] [Google Scholar]
- 13.Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. De Luca G, Gibson CM, Bellandi F, et al. Heart. 2008;94:1548–1558. doi: 10.1136/hrt.2008.141648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Naghavi M, Libby P, Falk E, et al. Circulation. 2003;108:1664–1672. doi: 10.1161/01.CIR.0000087480.94275.97. [DOI] [PubMed] [Google Scholar]
- 15.Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. Farag M, Spinthakis N, Gue YX, Srinivasan M, Sullivan K, Wellsted D, Gorog DA. Eur Heart J. 2019;40:295–305. doi: 10.1093/eurheartj/ehy656. [DOI] [PubMed] [Google Scholar]
- 16.Impaired spontaneous/endogenous fibrinolytic status as new cardiovascular risk factor?: JACC review topic of the week. Gorog DA, Lip GY. J Am Coll Cardiol. 2019;74:1366–1375. doi: 10.1016/j.jacc.2019.07.030. [DOI] [PubMed] [Google Scholar]
- 17.Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention. Christopoulos C, Farag M, Sullivan K, Wellsted D, Gorog DA. Thromb Haemost. 2017;117:457–470. doi: 10.1160/TH16-09-0712. [DOI] [PubMed] [Google Scholar]
- 18.Antithrombotic therapy for patients with STEMI undergoing primary PCI. Franchi F, Rollini F, Angiolillo DJ. Nat Rev Cardiol. 2017;14:361–369. doi: 10.1038/nrcardio.2017.18. [DOI] [PubMed] [Google Scholar]
- 19.Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay. Heestermans T, de Boer MJ, van Werkum JW, et al. EuroIntervention. 2011;7:442–448. doi: 10.4244/EIJV7I4A73. [DOI] [PubMed] [Google Scholar]
- 20.Prehospital clopidogrel administration in patients with ST-segment elevation myocardial infarction treated with primary PCI: real-life experience from the multicenter NRDES Registry. Rakowski T, Siudak Z, Dziewierz A, Sawina A, Dudek D. https://www.invasivecardiology.com/index.php/articles/prehospital-clopidogrel-administration-patients-st-segment-elevation-myocardial-infarction. J Invasive Cardiol. 2016;28:56–58. [PubMed] [Google Scholar]
- 21.P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: analysis from the SAMPA randomized trial. de FC Guimarães L, Généreux P, Silveira D, et al. Int J Cardiol. 2017;230:204–208. doi: 10.1016/j.ijcard.2016.12.173. [DOI] [PubMed] [Google Scholar]
- 22.Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Guimaraes PO, Tricoci P. Expert Opin Pharmacother. 2015;16:1983–1995. doi: 10.1517/14656566.2015.1074180. [DOI] [PubMed] [Google Scholar]
- 23.Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent? Gender difference in STEMI stratified on age. Otten AM, Maas AH, Ottervanger JP, et al. Eur Heart J Acute Cardiovasc Care. 2013;2:334–341. doi: 10.1177/2048872612475270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Rakowski T, Siudak Z, Dziewierz A, Dubiel JS, Dudek D. J Thromb Thrombolysis. 2012;34:397–403. doi: 10.1007/s11239-012-0764-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. Prasad A, Stone GW, Stuckey TD, et al. J Am Coll Cardiol. 2005;45:508–514. doi: 10.1016/j.jacc.2004.10.054. [DOI] [PubMed] [Google Scholar]
- 26.Admission homocysteine is an independent predictor of spontaneous reperfusion and early infarct-related artery patency before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Li J, Zhou Y, Zhang Y, Zheng J. BMC Cardiovasc Disord. 2018;18:125. doi: 10.1186/s12872-018-0868-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Predominance of STEMI and severity of coronary artery disease in a cohort of patients hospitalized with acute coronary syndrome: a report from ABC Medical School. Bacci MR, Fonseca FL, Nogueira LF, et al. Rev Assoc Med Bras. 2015;61:240–243. doi: 10.1590/1806-9282.61.03.24. [DOI] [PubMed] [Google Scholar]
- 28.Left circumflex coronary artery as the culprit vessel in st-segment-elevation myocardial infarction. Ghanim D, Kusniec F, Kinany W, et al. Tex Heart Inst J. 2017;44:320–325. doi: 10.14503/THIJ-16-5905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. Schaaf MJ, Mewton N, Rioufol G, et al. J Cardiol. 2016;67:248–253. doi: 10.1016/j.jjcc.2015.05.008. [DOI] [PubMed] [Google Scholar]
